FCFS

160

+1.52%↑

RPT.US

2.49

-1.19%↓

FCFS

160

+1.52%↑

RPT.US

2.49

-1.19%↓

FCFS

160

+1.52%↑

RPT.US

2.49

-1.19%↓

FCFS

160

+1.52%↑

RPT.US

2.49

-1.19%↓

FCFS

160

+1.52%↑

RPT.US

2.49

-1.19%↓

Search

Bayer AG

Cerrado

SectorFinanzas

28.37 -4.94

Resumen

Variación precio

24h

Actual

Mínimo

28.285

Máximo

28.39

Métricas clave

By Trading Economics

Ingresos

-1.5B

-190M

Ventas

-3B

11B

BPA

1.23

Rentabilidad por dividendo

0.42

Margen de beneficios

-1.769

Empleados

89,556

EBITDA

-3.4B

236M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+0.74% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.42%

3.89%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-545M

26B

Apertura anterior

33.31

Cierre anterior

28.37

Noticias sobre sentimiento de mercado

By Acuity

29%

71%

76 / 528 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Bayer AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 nov 2025, 07:32 UTC

Ganancias

Bayer Posts Net Loss on Litigation Hit

6 ago 2025, 06:18 UTC

Ganancias

Bayer Loss Widens on Litigation Charges

12 nov 2025, 11:15 UTC

Charlas de Mercado
Ganancias

Bayer's Crop Science Unit Drives Strong Results -- Market Talk

12 nov 2025, 06:33 UTC

Ganancias

Bayer Affirms Objective to Significantly Contain Litigation Risk by End of 2026

12 nov 2025, 06:31 UTC

Ganancias

Analysts Had Seen Bayer 3Q Net Loss at EUR413M

12 nov 2025, 06:31 UTC

Ganancias

Bayer 3Q Net Loss EUR963M

12 nov 2025, 06:30 UTC

Ganancias

Analysts Had Seen Bayer 3Q EBITDA Before Special Items at EUR1.27B

12 nov 2025, 06:30 UTC

Ganancias

Bayer 3Q EBITDA Before Special Items EUR1.51B

12 nov 2025, 06:30 UTC

Ganancias

Analysts Had Seen Bayer 3Q Sales at EUR9.69B

12 nov 2025, 06:30 UTC

Ganancias

Bayer 3Q Sales EUR9.66B

12 nov 2025, 06:30 UTC

Ganancias

Bayer Backs 2025 View

6 ago 2025, 15:01 UTC

Charlas de Mercado
Ganancias

Bayer Expects Bumper U.S. Crop -- Market Talk

6 ago 2025, 14:52 UTC

Charlas de Mercado

Bayer says Litigation Situation With Roundup 'Unsustainable' -- Market Talk

6 ago 2025, 09:05 UTC

Charlas de Mercado

Bayer Expects Weedkiller Dicamba Back on U.S. Market in 2026 -- Market Talk

6 ago 2025, 07:27 UTC

Charlas de Mercado
Ganancias

Bayer's Results Deliver Few Surprises -- Market Talk

6 ago 2025, 05:43 UTC

Ganancias

Bayer: Crop Science Division Now in a Position to Streamline Production and Operations

6 ago 2025, 05:43 UTC

Ganancias

Bayer: Making Headway on Plan to Improve Profitability in Agricultural Business

6 ago 2025, 05:42 UTC

Ganancias

Bayer Affirms Objective to Significantly Contain Litigation Risk by End of 2026

6 ago 2025, 05:41 UTC

Ganancias

Bayer Expects Significant Currency Fluctuations With Headwinds on Sales and Profits, Favorable Effects on Debt

6 ago 2025, 05:41 UTC

Ganancias

Bayer: 2H Will Be Marked by Progress on Strategic Priorities, Launches, Geopolitical and Currency Crosswinds

6 ago 2025, 05:33 UTC

Ganancias

Bayer 2Q Net Loss EUR199M

6 ago 2025, 05:32 UTC

Ganancias

Bayer Had Pre-Announced 2Q Ebitda Before Special Items at EUR2.1B

6 ago 2025, 05:32 UTC

Ganancias

Bayer 2Q Ebitda Before Special Items EUR2.11B

6 ago 2025, 05:32 UTC

Ganancias

Bayer Had Pre-Announced 2Q Sales at EUR10.7B

6 ago 2025, 05:32 UTC

Ganancias

Bayer 2Q Sales EUR10.74B

30 jun 2025, 15:09 UTC

Charlas de Mercado

Supreme Court Asks for Government's View on Bayer's Roundup Case -- Market Talk

5 jun 2025, 08:29 UTC

Charlas de Mercado

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30 may 2025, 13:47 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

27 may 2025, 12:22 UTC

Charlas de Mercado
Ganancias

Bayer's Prospects Are Improving -- Market Talk

16 may 2025, 13:42 UTC

Acciones populares

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

Comparación entre iguales

Cambio de precio

Bayer AG previsión

Precio Objetivo

By TipRanks

0.74% repunte

Estimación a 12 Meses

Media 28.61 EUR  0.74%

Máximo 35 EUR

Mínimo 23 EUR

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bayer AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

9 ratings

3

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

22.99 / 23.88Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

76 / 528 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
help-icon Live chat